Financing channel feed – Endpoints News

Financing channel feed

GenSight vet Combal grabs $40M from Novartis, Roche group for second-wave gene therapy biotech

9 years ago

Five months, $98.5M and a PhII drug from Novartis later, Magenta Therapeutics is flooring it

9 years ago

Way over budget and years late — AstraZeneca’s massive HQ project offers a troubling symbol

9 years ago

Shanghai-based EpimAb Bio grows global roots with $25M A round and a key assist by Robert Kamen

9 years ago

Ex-Dendreon chief Mitch Gold steers his way back to the public markets, looking to jumpstart a new clinical program

9 years ago

Hey Pfizer, Novartis and Eli Lilly. G1 Therapeutics says it can beat all of you in its $115M IPO

9 years ago

SV debuts a new, $400M fund with a big focus on biotech startups

9 years ago

Megadeals keep investments up in lifesci’s Q1, but the tempo continues to slow for biotech

9 years ago

Jeremy Levin spotlights a trendy new way to build a pipeline with his $86M IPO for Ovid

9 years ago

A serial biotech startup team is back in business, armed with $40M and a focus on NASH

9 years ago

Frequency Therapeutics gets a $32M startup round to help fine tune its hearing loss drug R&D

9 years ago

In the hunt for a $100M IPO, Biohaven polishes up discards from Bristol-Myers, AstraZeneca

9 years ago

Armed with deals, dollars and the promise of upcoming data, Zymeworks files $75M IPO

9 years ago

Solid Biosciences appears to be prepping for an IPO with $50M round for Duchenne gene therapy

9 years ago

Money, brains and ambition: Third Rock startup Tango launches with $55M and a stellar crew of scientific advisers

9 years ago

Virtual biotech Antiva sets out on a big R&D quest, armed with a $22M round for an HPV therapy

9 years ago

Novartis-backed Ionis subsidiary Akcea maps a $100M IPO as it steers a lead drug to regulators

9 years ago

That $95M Merck gamble to acquire cCAM? It didn’t pay off.

9 years ago

BioClin scores a $30M raise from marquee investors to fuel mid-stage work on a new cancer drug

9 years ago

SutroVax raises $64M with plans to challenge Pfizer’s megablockbuster Prevnar 13 for the heavyweight title in vaccines

9 years ago

New biotech venture fund debuts with $300M for a mix of US and European players

9 years ago

Gates vets raise a $200M life sci fund for avant-garde genomic biotechs and digital health players

9 years ago

On again, ex-Google superstar Bill Maris is said to bankroll a $100M biotech fund

9 years ago

Pushing ahead with cancer drug research, Peloton brings its latest round to $75M

9 years ago

First page Previous page 140 141 142143144 145 146 Next page Last page